Home » Stocks » HOWL

Werewolf Therapeutics, Inc. (HOWL)

Stock Price: $11.63 USD 0.03 (0.26%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $11.30 -0.33 (-2.84%) May 14, 7:32 PM
Market Cap 320.13M
Revenue (ttm) n/a
Net Income (ttm) -28.22M
Shares Out 27.53M
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $11.63
Previous Close $11.60
Change ($) 0.03
Change (%) 0.26%
Day's Open 11.50
Day's Range 11.50 - 12.27
Day's Volume 75,323
52-Week Range 11.23 - 23.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of...

2 weeks ago - InvestorPlace

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...

2 weeks ago - GlobeNewsWire

After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO.

1 month ago - FierceBiotech

Werewolf Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About HOWL

Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, ... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Apr 30, 2021
CEO
Daniel J. Hicklin, Ph.D.
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
HOWL
Full Company Profile

Financial Performance

Financial Statements